SSRI-induced apathy syndrome: a clinical review.
The authors review the literature pertaining to selective serotonin reuptake inhibitor (SSRI)-induced apathy syndrome. A literature search of Medline and International Pharmaceutical Abstracts from 1970 to the present was performed for relevant articles. Twelve relevant case reports and one open-label treatment trial were identified. An amotivational, or apathy, syndrome has been reported in a number of patients receiving SSRI treatment over the last decade. This adverse effect has been noted to be dose-dependent and reversible, but is often unrecognized. This phenomenon has caused significant negative consequences for adults as well as social and academic difficulties in adolescents.
Barnhart
W Jason
WJ
Department of Behavioral Health and Psychiatry, North Colorado Medical Center, Greeley 80631, USA.
Makela
Eugene H
EH
Latocha
Melissa J
MJ
D000293:Adolescent; D000328:Adult; D002648:Child; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy; D008875:Middle Aged; D019964:Mood Disorders / Q000139:chemically induced*; D009042:Motivation; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D013577:Syndrome
D017367:Selective Serotonin Reuptake Inhibitors